Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 3/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | CASP7 | P55210 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL893013 | 0.84 | TDP1 (0.46) | TDP1TSHRMAPTALDH1A1ALOX15 | |
| SCHEMBL9105174 | 0.80 | TP53 (0.46) | TP53MAPTALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL10344642 | 0.76 | TAAR1 (0.36) | TDP1TSHRMAPTTAAR1ALDH1A1 | |
| SCHEMBL4914912 | 0.75 | TDP1 (0.41) | TDP1TSHRMAPTALDH1A1ALOX15 | |
| SCHEMBL10444725 | 0.71 | TDP1 (0.38) | TDP1TSHRMAPTALDH1A1ALOX15 | |
| SCHEMBL10879280 | 0.71 | TDP1 (0.38) | TP53TDP1TSHRMAPTALDH1A1 | |
| SCHEMBL1323657 | 0.71 | TDP1 (0.45) | TDP1TSHRMAPTALDH1A1ALOX15 | |
| SCHEMBL5606801 | 0.71 | MAPT (0.47) | TDP1TSHRMAPTALDH1A1L3MBTL1 | |
| SCHEMBL11541977 | 0.71 | TDP1 (0.38) | TDP1TSHRMAPTALDH1A1ALOX15 | |
| Hydrochloric Acid SCHEMBL9281942 | 0.70 | TP53 (0.33) | TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150374706-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | GALLEON PHARMACEUTICALS, INC. | 2015-12-31 | — | — | US | claimed |
| US-20140371224-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | GALLEON PHARMACEUTICALS, INC. | 2014-12-18 | — | — | US | claimed |
| US-20120295911-A1 | Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases | GALLEON PHARMACEUTICALS, INC. | 2012-11-22 | — | — | US | claimed |
| US-20120142647-A1 | Novel Compounds as Respiratory Stimulants for Treatment of Breathing Control Disorders or Diseases | GALLEON PHARMACEUTICALS, INC. | 2012-06-07 | — | — | US | claimed |
| US-20260137675-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS TO TREAT DRUG OVERDOSE | ENALARE THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-12544369-B2 | Methods and pharmaceutical compositions to treat drug overdose | ENALARE THERAPEUTICS INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20250325554-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS TO TREAT RESPIRATORY DEPRESSION IN PATIENTS | ENALARE THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250114370-A1 | METHODS AND COMPOSITIONS FOR TREATING DRUG OVERDOSE | ENALARE THERAPEUTICS INC (US) | 2025-04-10 | — | — | US | disclosed |
| US-20250032496-A1 | METHODS OF TREATING RESPIRATORY DEPRESSION MODULATED BY A NON-OPIOID AGENT | ENALARE THERAPEUTICS INC (US) | 2025-01-30 | — | — | US | disclosed |
| US-12138267-B2 | Methods of treating respiratory depression modulated by a non-opioid agent | ENALARE THERAPEUTICS INC. (US) | 2024-11-12 | — | — | US | disclosed |
| US-20240238303-A1 | LARGE-CONDUCTANCE POTASSIUM CHANNEL MODULATORS, COMPOSITIONS THEREOF, METHODS OF MANUFACTURING THEREOF, AND METHODS OF USE THEREOF | ENALARE THERAPEUTICS INC (US) | 2024-07-18 | — | — | US | disclosed |
| US-20230414624-A1 | METHODS OF TREATING NEUROLOGICAL VENTILATORY INSUFFICIENCY | ENALARE THERAPEUTICS INC (US) | 2023-12-28 | — | — | US | disclosed |
| US-20220241268-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS TO TREAT DRUG OVERDOSE | ENALARE THERAPEUTICS INC. | 2022-08-04 | — | — | US | disclosed |
| US-20160256463-A1 | NOVEL COMPOUNDS AS RESPIRATORY STIMULANTS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | GALLEON PHARMACEUTICALS INC (US) | 2016-09-08 | — | — | US | disclosed |
| US-9351972-B2 | Compounds as respiratory stimulants for treatment of breathing control disorders or diseases | GALLEON PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20150374706-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | GALLEON PHARMACEUTICALS, INC. | 2015-12-31 | — | — | US | disclosed |
| US-9162992-B2 | Compounds and compositions for treatment of breathing control disorders or diseases | GALLEON PHARMACEUTICALS, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-20140371224-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | GALLEON PHARMACEUTICALS, INC. | 2014-12-18 | — | — | US | disclosed |
| US-20120295911-A1 | Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases | GALLEON PHARMACEUTICALS, INC. | 2012-11-22 | — | — | US | disclosed |
| US-20120142647-A1 | Novel Compounds as Respiratory Stimulants for Treatment of Breathing Control Disorders or Diseases | GALLEON PHARMACEUTICALS, INC. | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12544369-B2 | Methods and pharmaceutical compositions to treat drug overdose | OPRK1, OPRD1, OPRM1 | TP53 4880/4885TDP1 1783/4885TSHR 371/4885 |
| US-20120142647-A1 | Novel Compounds as Respiratory Stimulants for Treatment of Breathing Control Disorders or Diseases | MTNR1B, CHRM3, ADRA2C | TP53 4878/4885TDP1 1257/4885TSHR 1976/4885 |
| US-12138267-B2 | Methods of treating respiratory depression modulated by a non-opioid agent | OPRK1, OPRM1, OPRD1 | TP53 4883/4885TDP1 3301/4885TSHR 1902/4885 |
| US-20260137675-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS TO TREAT DRUG OVERDOSE | ADRA2B, ADRB1, ADRB2 | TP53 4693/4885TDP1 1404/4885TSHR 382/4885 |
| US-20120295911-A1 | Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases | PER2, SMPD4, NDUFB5 | TP53 4818/4885TDP1 3068/4885TSHR 3789/4885 |
| US-20250325554-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS TO TREAT RESPIRATORY DEPRESSION IN PATIENTS | NDUFB6, NDUFB7, CHRM5 | TP53 4877/4885TDP1 1479/4885TSHR 2765/4885 |
| US-20250032496-A1 | METHODS OF TREATING RESPIRATORY DEPRESSION MODULATED BY A NON-OPIOID AGENT | OPRK1, OPRM1, OPRD1 | TP53 4883/4885TDP1 3301/4885TSHR 1902/4885 |
| US-20140371224-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | PER2, MTNR1B, NDUFB5 | TP53 4855/4885TDP1 3385/4885TSHR 3888/4885 |
| US-20160256463-A1 | NOVEL COMPOUNDS AS RESPIRATORY STIMULANTS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | P2RX5, HRH2, ADRA2C | TP53 4850/4885TDP1 293/4885TSHR 1896/4885 |
| US-20220241268-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS TO TREAT DRUG OVERDOSE | OPRK1, OPRM1, ADRB1 | TP53 4639/4885TDP1 1945/4885TSHR 470/4885 |
| US-20250114370-A1 | METHODS AND COMPOSITIONS FOR TREATING DRUG OVERDOSE | ADRA2A, ADRA2C, OPRM1 | TP53 4678/4885TDP1 1265/4885TSHR 825/4885 |
| US-20240238303-A1 | LARGE-CONDUCTANCE POTASSIUM CHANNEL MODULATORS, COMPOSITIONS THEREOF, METHODS OF MANUFACTURING THEREOF, AND METHODS OF USE THEREOF | KCNN2, KCNN1, KCNN3 | TP53 4286/4885TDP1 4063/4885TSHR 3264/4885 |
| US-20150374706-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | PER2, SMPD4, NDUFB5 | TP53 4818/4885TDP1 3068/4885TSHR 3789/4885 |
| US-20230414624-A1 | METHODS OF TREATING NEUROLOGICAL VENTILATORY INSUFFICIENCY | SDHA, NDUFB7, OTC | TP53 4878/4885TDP1 1744/4885TSHR 3617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.